findmyKOL

Alexey Danilov, MD

Enriched profile

Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation; Co-Director, Toni Stephenson Lymphoma Center, City of Hope · City of Hope National Medical Center

ORCIDNPI
Region🇺🇸 Duarte, CA · West · United StatesSpecialtyHematologyFocusHematology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2021–2026

Alexey Danilov is Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation; Co-Director, Toni Stephenson Lymphoma Center, City of Hope at City of Hope National Medical Center. OpenAlex indexes 632 publications with 7,234 citations (h-index 41); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Alexey Danilov, MD, is Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center, Duarte, CA. The public record shows 632 publications with 7,234 citations (h-index 41), centered on Hematology. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 36 companies, 3 NIH-funded awards (2021–2026).

  • Most recent indexed publication: 2026 · Research square
  • Top research focus: Hematology
  • 14 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 36 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)10 trialsLymphoma10 trialsLeukemia, Lymphocytic, Chronic, B-Cell10 trialsLeukemia, Lymphoid10 trialsLymphoma, Large B-Cell, Diffuse3 trialsLymphoma, B-Cell3 trialsLymphoma, Non-Hodgkin2 trialsLymphoma, Follicular2 trialsHodgkin Disease2 trialsLeukemia, Prolymphocytic1 trialLeukemia, Prolymphocytic, B-Cell1 trialAnemia, Hemolytic, Autoimmune1 trialAnemia, Hemolytic1 trialRecurrence1 trialCOVID-191 trialColorectal Cancer1 trialKidney Cancer / RCC1 trialHepatobiliary Cancer1 trial

Research focus

OpenAlex concept fingerprint
Hematology

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trialsIndustry payments45Publications1Calquencegeneric · AcalabrutinibClinical trialsIndustry payments26Publications2Imbruvicageneric · IbrutinibClinical trialsIndustry payments12Publications4

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments59BeiGene USA, Inc.Clinical trialsIndustry payments53AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments37

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
632publications

Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.

7,234citations

Total citations across indexed works.

41h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials
36companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 2021–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    77.3%
    Kinase inhibitor77.3%
    Brukinsa53%Calquence47%
    Part D<11 patients
  • Dermatology

    12.9%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.9%
    Acyclovir100%
    Part D<11 patients
  • Musculoskeletal

    9.8%
    Xanthine oxidase inhibitor9.8%
    Allopurinol100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

3 NIH research awards on record, funded 20212026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/Alexey-Danilov-2259981205

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • Doximity

    doximity.com/pub/alexey-danilov-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/alexey-danilov-753586b9

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/OncLive/videos/alexey-danilov-md-phd-of-city-of-hope-discusses-frontline-treatment-selection-fo/759846973088769

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com
  • Other

    onclive.com/authors/alexey-danilov-md-phd-city-of-hope

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com
  • LinkedIn

    LinkedIn profile identifies him as Associate Director for Clinical Sciences, City of Hope (auth-walled; corroborated via SERP snippet only)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    PhD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com
  • Fellowship

    Hematology/Oncology, Tufts Medical Center, Boston, MA

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org

Editorial & leadership roles

journal and society appointments
  • Director

    Early Phase Therapeutics Program, City of Hope

    2024
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beckersoncology.com
  • Co-Director

    Toni Stephenson Lymphoma Center, City of Hope

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com
  • Associate Director for Clinical Sciences

    City of Hope Comprehensive Cancer Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beckersoncology.com
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.